Molecular Oncology, EarlyView.Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon +13 more
wiley +1 more source
Boron-10 loaded inorganic shielding material [PDF]
, 1972 Shielding material containing Boron 10 and gadoliunium for neutron absorption has been developed to reduce interference from low energy neutrons in measurement of fission neutron spectrum using Li-6 fast neutron ...
Baker, S. I., Ryskiewicz, R. S.
core +1 more source
Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide. [PDF]
, 2014 Sucroferric oxyhydroxide (VELPHORO(®)) is a polynuclear iron-based phosphate binder recently approved for the treatment of hyperphosphataemia in patients with chronic kidney disease (CKD). As a number of the available phosphate binders do not provide the
Cozzolino, M. +4 more
core +1 more source
Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition
Molecular Oncology, EarlyView.We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li +10 more
wiley +1 more source
Phosphate-control adherence in hemodialysis patients: current perspectives
Patient Preference and Adherence, 2018 Ebele M Umeukeje,1–3 Amanda S Mixon,3,4 Kerri L Cavanaugh1–3 1Vanderbilt Center for Kidney Disease, Nashville, TN, USA; 2Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville TN, USA; 3Vanderbilt ...
Umeukeje EM, Mixon AS, Cavanaugh KL
doaj
Al-Mustansiriyah Journal of Pharmaceutical Sciences, 2020 Background: The complications of End Stage Renal Disease ESRD attributed to high morbidity and mortality such as hyperphosphatemia and vascular disease.
Rana Bahaa Mohammed +2 more
doaj +1 more source
93 Changes in Mineral Bone Disorder Biomarkers and Phosphate Binder (PB) Pills/Day in Hemodialysis (HD) Patients Switching From Ferric Citrate (FC) to Sucroferric Oxyhydroxide (SO): A One-Year Follow Up Analysis [PDF]
, 2022 openalex +1 more source
The effect of intravenous vitamin C on the phosphorus level reduction in hemodialysis patients: A double blind randomized clinical trial [PDF]
, 2012 Aim The majority of hemodialysis patients are hyperphosphate-mic. Hyperphosphatemia in these patients can lead to renal oste-odystrophy, vascular calcifcation, cardiovascular events, and is independently associated with mortality risk.
Aarabi, M. +3 more
core
Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity
Molecular Oncology, EarlyView.Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung +17 more
wiley +1 more source